ALXO Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Stats
Today's Volume	612 172
Average Volume	1.28M
Market Cap	414.74M
EPS	$0 ( 2023-11-14 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.33
ATR14	$1.024 (12.31%)

Insider Trading

Date	Person	Action	Amount	type
2023-09-08	Lettmann Jason	Buy	1 200 000	Employee Stock Option (right to buy)
2023-07-25	Randolph Sophia	Buy	34 000	Common Stock
2023-07-25	Randolph Sophia	Buy	107 000	Common Stock
2023-07-25	Pinto Shelly	Buy	26 000	Common Stock
2023-07-25	Pinto Shelly	Buy	36 000	Employee Stock Option (right to buy)

INSIDER POWER
92.58
Last 97 transactions
Buy: 2 761 443 \| Sell: 658 297

Correlation (AI algo v.1.1b): Undervalued: 0.63% $8.37 paired level. (The Algo Track The Changes Of The Most Correlated Stocks In Realtime And Give An Instant Update)

Volume Correlation

Long: -0.73 (moderate negative)

Short: -0.52 (weak negative)

Signal:(52) Neutral

ALX Oncology Holdings Correlation

10 Most Positive Correlations
VWE	0.963
NAKD	0.962
AYTU	0.957
SIRI	0.956
IBRX	0.953
TENX	0.953
LAWS	0.952
GSMG	0.952
UTHR	0.951
JAGX	0.947

10 Most Negative Correlations
NSIT	-0.974
OVLY	-0.971
SJ	-0.97
GXII	-0.967
BRIVU	-0.963
TETC	-0.961
MCAA	-0.961
MLTX	-0.961
ACVA	-0.961
HERA	-0.96

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

ALX Oncology Holdings Correlation - Currency/Commodity

-0.63
( weak negative )

0.09
( neutral )

0.00
( neutral )

-0.51
( weak negative )

0.00
( neutral )

-0.68
( moderate negative )

ALX Oncology Holdings Financials

Annual	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-3.03

Q3	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-1.240

Q2	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.840

Q1	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.700

ALX Oncology Holdings

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.